Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-upTwo biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for Share XNeurocrine and Xenon agree $1.75bn epilepsy R&D tie-uphttps://pharmaphorum.com/news/neurocrine-and-xenon-agree-1-75bn-epilepsy-rd-tie-up/
Alkermes bolts on Rodin Therapeutics to bulk up thin pipelineAlkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative Share XAlkermes bolts on Rodin Therapeutics to bulk up thin pipelinehttps://pharmaphorum.com/news/alkermes-bolts-on-rodin-therapeutics-to-bulk-up-thin-pipeline/
Merck builds in CNS diseases with $576m Calporta buyMerck & Co has had mixed fortunes in neurological diseases of late, but remains committed to the category Share XMerck builds in CNS diseases with $576m Calporta buyhttps://pharmaphorum.com/news/merck-builds-in-cns-diseases-with-576m-calporta-buy/
Biogen bags FDA okay for Tecfidera follow-up VumerityBiogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to Share XBiogen bags FDA okay for Tecfidera follow-up Vumerityhttps://pharmaphorum.com/news/biogen-fda-tecfidera-vumerity-ms/
Searching for new hope in Alzheimer’sFor the best part of two decades, it seemed as if pharma hit a brick wall as it Share XSearching for new hope in Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/searching-for-new-hope-in-alzheimers/
FDA approves Lilly’s new migraine attack drug, rival from Allergan could followThe FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms Share XFDA approves Lilly’s new migraine attack drug, rival from Allergan could followhttps://pharmaphorum.com/news/fda-approves-lillys-new-migraine-attack-drug-rival-from-allergan-could-follow/
After Alzheimer’s trial woes, Biogen’s R&D chief quits to head up biotech VCMichael Ehlers is to quit as head of Biogen’s troubled R&D outfit, taking a role as chief executive Share XAfter Alzheimer’s trial woes, Biogen’s R&D chief quits to head up biotech VChttps://pharmaphorum.com/news/after-alzheimers-trial-woes-biogens-rd-chief-quits-to-head-up-biotech-vc/
GW Pharma’s cannabis-derived epilepsy drug approved in EUGW Pharmaceuticals’ cannabis-derived drug Epidyolex has been approved in Europe for two kinds of rare childhood epilepsy. The Share XGW Pharma’s cannabis-derived epilepsy drug approved in EUhttps://pharmaphorum.com/news/gw-pharmas-cannabis-derived-epilepsy-drug-approved-in-eu/
bluebird presents long-term data from CALD gene therapybluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy Share Xbluebird presents long-term data from CALD gene therapyhttps://pharmaphorum.com/news/bluebird-presents-long-term-data-from-cald-gene-therapy/
